Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2

Authors: King, Brett ^{a, ∗}, Ohyama, Manabu ^b, Senna, Maryanne ^c, Shapiro, Jerry ^d, Dutronc, Yves ^e, Durand, Frederick ^f, Liu, Chunyuan ^e, Yu, Guanglei ^e, Kolodsick, Jill ^e, Chiasserini, Chiara ^e, Somani, Najwa ^e, Piraccini, Bianca Maria ^{g, h}

Source: In Journal of the American Academy of Dermatology February 2025 92(2):299-306

Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy

Authors: Costanzo, Antonio, Tanaka, Akio, Torres, Tiago, Pérez‐García, Bibiana, Sontag, Angelina, Chen, Yun‐Fei, Yang, Fan Emily, Kolodsick, Jill, Torisu‐Itakura, Hitoe, Somani, Najwa

Source: JEADV clinical practice. 2(3):583-589

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193840015.0x000001&indx=1&recIds=ETOCvdc_100193840015.0x000001

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

Authors: Soung, Jennifer, Cather, Jennifer C., Gooderham, Melinda, Ryan, Caitriona, Somani, Najwa, Feely, Meghan, See, Kyoungah, Burge, Russel, Elrayes, Mohamed, Gallo, Gaia, Armstrong, April W.

Source: JEADV clinical practice. 2(2):282-292

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193839419.0x000001&indx=1&recIds=ETOCvdc_100193839419.0x000001

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Authors: Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri L., Lew, Carolyn R., Zimmerman, Nicole M., Atiya, Bilal, Murage, Mwangi J.

Source: In Journal of the American Academy of Dermatology March 2022 86(3):581-589

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

Authors: Hebert, Adelaide A., Bobonich, Margaret A., Rodriguez Capriles, Claudia, Gallo, Gaia, Li, Lingnan, Somani, Najwa, Ridenour, Terri, Wang, Yan, Edson‐Heredia, Emily, Becker, Emily M.

Source: Pediatric dermatology. 39(1):55-60

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100139828409.0x000001&indx=1&recIds=ETOCvdc_100139828409.0x000001

Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings

Authors: Blauvelt, Andrew, Shi, Nianwen, Murage, Mwangi J., Kern, Scott A., Somani, Najwa, Burge, Russel, Ridenour, Terri L., Lew, Carolyn R., Zimmerman, Nicole M., Zhu, Baojin

Source: Journal of medical economics. 25(1):741-749

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100184408803.0x000001&indx=1&recIds=ETOCvdc_100184408803.0x000001

Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study

Authors: Blauvelt, Andrew, Shi, Nianwen, Murage, Mwangi J., Ridenour, Terri Lynn, Lew, Carolyn R., Somani, Najwa, Zhu, Baojin, Zimmerman, Nicole M., Kern, Scott A., Burge, Russel T.

Source: Journal of drugs in dermatology. 21(4):399-407

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN629021668&indx=1&recIds=ETOCRN629021668

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.

Authors: King, Brett, Ko, Justin, Kwon, Ohsang, Vañó-Galván, Sergio, Piraccini, Bianca Maria, Dutronc, Yves, Yu, Guanglei, Liu, Chunyuan, Somani, Najwa, Ball, Susan, Mesinkovska, Natasha A.

Source: JAMA Dermatology; Oct2024, Vol. 160 Issue 10, p1075-1081, 7p

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.

Authors: Egeberg, Alexander, Hawkes, Jason E., Somani, Najwa, Burge, Russel, See, Kyoungah, Gallo, Gaia, McKean-Matthews, Missy, Gooderham, Melinda, Han, George, Armstrong, April

Source: Dermatology & Therapy; Apr2024, Vol. 14 Issue 4, p1007-1018, 12p

Subject Terms: ITCHING, PATIENT reported outcome measures, SCALP, QUALITY of life, CLINICAL trials, TREATMENT effectiveness

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.

Authors: Taylor, Susan, Korman, Neil J., Tsai, Tsen-Fang, Shimomura, Yutaka, Feely, Meghan, Dutronc, Yves, Wu, Wen-Shuo, Somani, Najwa, Tosti, Antonella

Source: Dermatology & Therapy; Dec2023, Vol. 13 Issue 12, p3181-3191, 11p

Subject Terms: ALOPECIA areata, BARICITINIB, CLINICAL trials, HAIR growth

Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.

Authors: Ko, Justin M., Mayo, Tiffany T., Bergfeld, Wilma F., Dutronc, Yves, Yu, Guanglei, Ball, Susan G., Somani, Najwa, Craiglow, Brittany G.

Source: JAMA Dermatology; Sep2023, Vol. 159 Issue 9, p970-976, 7p

52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib

Authors: King, Brett, Senna, Maryanne, Ohyama, Manabu, Dutronc, Yves, Lu, Na, Chiasserini, Chiara, Somani, Najwa, Piraccini, Bianca Maria

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB340-AB340

49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2

Authors: Senna, Maryanne, Mostaghimi, Arash, Ohyama, Manabu, Sinclair, Rodney, Chiasserini, Chiara, Dutronc, Yves, Somani, Najwa, Yu, Guanglei, Kolodsick, Jill, King, Brett

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB251-AB251

Subcutaneous myxopapillary ependymal rest: A potential sign of spinal dysraphism

Authors: Burdick, Laura M., Bergfeld, Wilma, Somani, Najwa, Piliang, Melissa

Source: In Journal of the American Academy of Dermatology October 2011 65(4):851-854

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.

Authors: Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri, Kern, Scott, Lew, Carolyn, Zimmerman, Nicole, Murage, Mwangi

Source: Clinical Drug Investigation; Mar2023, Vol. 43 Issue 3, p185-196, 12p

Subject Terms: HEALTH insurance claims, DRUG prices, PSORIASIS, PRICE indexes, ECONOMIC stabilization, MEDICAL care cost statistics, COST estimates, DRUGSTORES, SPECIALTY pharmacies

34 - Antiandrogens and Androgen Inhibitors

Authors: Somani, Najwa, Sawaya, Marty E.

Source: In Comprehensive Dermatologic Drug Therapy Edition: Fourth Edition. 2021:366-381

A histologic review of 27 patients with lichen planopilaris

Authors: Tandon, Yasmeen K., Somani, Najwa, Cevasco, Nathaniel C., Bergfeld, Wilma F.

Source: In Journal of the American Academy of Dermatology 2008 59(1):91-98

41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata

Authors: Shapiro, Jerry, Ko, Justin, Egeberg, Alexander, Somani, Najwa, Jedynak, Jakub, Torisu-Itakura, Hitoe, Yu, Guanglei, Lu, Na, Craiglow, Brittany

Source: In Journal of the American Academy of Dermatology September 2023 89(3) Supplement:AB127-AB127

26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients

Authors: Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Ridenour, Terri L., Somani, Najwa, Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Kern, Scott A., Zimmerman, Nicole M., Murage, Mwangi J.

Source: Journal of the American Academy of Dermatology. 85(3):AB114-AB114

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134188110.0x000001&indx=1&recIds=ETOCvdc_100134188110.0x000001

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.

Authors: Paller, Amy S., Seyger, Marieke M. B., Magariños, Gabriel A., Pinter, Andreas, Cather, Jennifer C., Rodriguez-Capriles, Claudia, Zhu, Danting, Somani, Najwa, Garrelts, Alyssa, Papp, Kim A., IXORA-PEDS Investigators

Source: JAMA Dermatology; May2022, Vol. 158 Issue 5, p533-541, 9p